175 related articles for article (PubMed ID: 12060125)
1. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
Sahara N; Takeshita A; Shigeno K; Fujisawa S; Takeshita K; Naito K; Ihara M; Ono T; Tamashima S; Nara K; Ohnishi K; Ohno R
Br J Haematol; 2002 Jun; 117(4):882-5. PubMed ID: 12060125
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma.
Kraj M; Sokołowska U; Kopeć-Szlezak J; Pogłód R; Kruk B; Woźniak J; Szpila T
Leuk Lymphoma; 2008 Feb; 49(2):298-305. PubMed ID: 18231917
[TBL] [Abstract][Full Text] [Related]
3. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).
Van Camp B; Durie BG; Spier C; De Waele M; Van Riet I; Vela E; Frutiger Y; Richter L; Grogan TM
Blood; 1990 Jul; 76(2):377-82. PubMed ID: 1695113
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens.
Sahara N; Takeshita A
Leuk Lymphoma; 2004 Jan; 45(1):61-5. PubMed ID: 15061198
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma.
Dahl IM; Rasmussen T; Kauric G; Husebekk A
Br J Haematol; 2002 Feb; 116(2):273-7. PubMed ID: 11841427
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.
Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K
Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099
[TBL] [Abstract][Full Text] [Related]
8. Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study.
Schwartz TH; Rhiew R; Isaacson SR; Orazi A; Bruce JN
Neurosurgery; 2001 Nov; 49(5):1039-44; discussion 1044-5. PubMed ID: 11846895
[TBL] [Abstract][Full Text] [Related]
9. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome.
Koumpis E; Tassi I; Malea T; Papathanasiou K; Papakonstantinou I; Serpanou A; Tsolas E; Kapsali E; Vassilakopoulos TP; Papoudou-Bai A; Hatzimichael E
Pathol Res Pract; 2021 Sep; 225():153567. PubMed ID: 34352440
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?
Mathew P; Ahmann GJ; Witzig TE; Roche PC; Kyle RA; Greipp PR
Br J Haematol; 1995 Jun; 90(2):459-61. PubMed ID: 7540857
[TBL] [Abstract][Full Text] [Related]
11. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications.
García-Sanz R; González M; Orfão A; Moro MJ; Hernández JM; Borrego D; Carnero M; Casanova F; Bárez A; Jiménez R; Portero JA; San Miguel JF
Br J Haematol; 1996 Apr; 93(1):81-8. PubMed ID: 8611480
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic effect of beta 2-microglobulin in multiple myeloma].
Ortega F; González M; Moro MJ; Gascón A; Duarte I; Martín M; Hernández J; Jiménez-Galindo R; Portero JA; Sanz M
Med Clin (Barc); 1992 Nov; 99(17):645-8. PubMed ID: 1447935
[TBL] [Abstract][Full Text] [Related]
13. Determination of plasma cell secreting potential as an index of maturity of myelomatous cells and a strong prognostic factor.
Symeonidis A; Kouraklis-Symeonidis A; Grouzi E; Zolota V; Melachrinou M; Kourea K; Fragopanagou E; Giannakoulas N; Seimeni U; Tiniakou M; Matsouka P; Zoumbos N
Leuk Lymphoma; 2002 Aug; 43(8):1605-12. PubMed ID: 12400603
[TBL] [Abstract][Full Text] [Related]
14. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.
Rawstron A; Barrans S; Blythe D; Davies F; English A; Pratt G; Child A; Morgan G; Jack A
Br J Haematol; 1999 Jan; 104(1):138-43. PubMed ID: 10027726
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.
Chang H; Samiee S; Yi QL
Leuk Lymphoma; 2006 Jan; 47(1):43-7. PubMed ID: 16321826
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leonés (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.
García-Sanz R; Orfão A; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
Br J Haematol; 1995 May; 90(1):106-12. PubMed ID: 7786771
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1).
Menke DM; Horny HP; Griesser H; Atkinson EJ; Kaiserling E; Kyle RA
J Clin Pathol; 1998 Jun; 51(6):432-7. PubMed ID: 9771441
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients.
ElMenshawy N; Farag NA; Atia DM; Abousamra N; Shahin D; Fawzi E; Ghazi H; El-Kott AF; Eissa M
Cancer Invest; 2021 Oct; 39(9):777-782. PubMed ID: 34344244
[TBL] [Abstract][Full Text] [Related]
19. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
[TBL] [Abstract][Full Text] [Related]
20. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]